A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Clinical trial NCT03209973 · COMPLETED
Trial details
- NCT number
- NCT03209973
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-21
- Primary completion
- 2020-11-02
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.